P
Peter M. Rothwell
Researcher at University of Oxford
Publications - 815
Citations - 77220
Peter M. Rothwell is an academic researcher from University of Oxford. The author has contributed to research in topics: Stroke & Population. The author has an hindex of 134, co-authored 779 publications receiving 67382 citations. Previous affiliations of Peter M. Rothwell include Leicester Royal Infirmary & University of Edinburgh.
Papers
More filters
Journal ArticleDOI
Is carotid artery stenting superior to carotid endarterectomy in symptomatic stroke patients
TL;DR: IsCarotid artery stenting superior to carotid endarterectomy in symptomatic stroke patients?
Journal ArticleDOI
Local Versus General Anesthesia for Carotid Endarterectomy: Cochrane Review.
Amaraporn Rerkasem,Sothida Nantakool,Saritphat Orrapin,Peter M. Rothwell,Dominic P.J. Howard,Kittipan Rerkasem +5 more
Posted ContentDOI
Automated Detection of Candidate Subjects with Cerebral Microbleeds using Machine Learning
Vaanathi Sundaresan,Christoph Arthofer,Christoph Arthofer,Giovanna Zamboni,Giovanna Zamboni,Robert A. Dineen,Peter M. Rothwell,Stamatios N. Sotiropoulos,Stamatios N. Sotiropoulos,Dorothee P. Auer,D Tozer,Hugh S. Markus,Karla L. Miller,Iulius Dragonu,Nikola Sprigg,Fidel Alfaro-Almagro,Mark Jenkinson,Mark Jenkinson,Mark Jenkinson,Ludovica Griffanti +19 more
TL;DR: In this paper, a machine learning-based, computationally light pipeline was proposed to detect CMB candidate subjects from a larger dataset, UK Biobank, using a machine-learning-based approach.
Journal Article
Long-term risk of stroke and coronary events after focal and non-focal transient neurological attacks: A population-based study
M A Tuna,Linxin Li,A Tornada,L C Gaziano,Sergei A. Gutnikov,Z Mehta,Peter M. Rothwell,O V Study +7 more
Journal Article
Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients
Gaia Sirimarco,Julien Labreuche,Eric Bruckert,Larry B. Goldstein,K M Fox,Peter M. Rothwell,Pierre Amarenco +6 more
TL;DR: In this article, the authors studied subjects with stroke or transient ischemic attack in the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin With Terutroban in Patients With a History of Ischemia Stroke or Transient Ischemmic Attack (PERFORM) and Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trials who were treated with a statin and who had high-density lipoprotein cholesterol and triglycerides measurements 3 months after randomization (n=10 498 and 2900, respectively